How to buy Citius Pharmaceuticals shares | 11 March price $1.865

How to buy Citius Pharmaceuticals shares | $1.865

Own Citius Pharmaceuticals shares in just a few minutes. Share price changes are updated daily.

Citius Pharmaceuticals, Inc (CTXR) is a leading biotechnology business based in the US. It opened the day at $1.84 after a previous close of $1.82. During the day the price has varied from a low of $1.785 to a high of $1.9. The latest price was $1.865 (25 minute delay). Citius Pharmaceuticals is listed on the NASDAQ and employs 10 staff. All prices are listed in US Dollars.

How to buy shares in Citius Pharmaceuticals

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: CTXR in this case.
  5. Research Citius Pharmaceuticals shares. The platform should provide the latest information available.
  6. Buy your Citius Pharmaceuticals shares. It's that simple.
The whole process can take as little as 15 minutes.

Citius Pharmaceuticals share price

Use our graph to track the performance of CTXR stocks over time.

Citius Pharmaceuticals shares at a glance

Information last updated 2021-03-11.
Previous close$1.82
Change $0.045
Change % 2.4725%
Volume 3,677,144
Information last updated 2021-04-15.
52-week range$0.64 - $2.5
50-day moving average $1.9029
200-day moving average $1.3381
Wall St. target price$6
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.821
eToro Free Stocks

Invest in Citius Pharmaceuticals shares with 0% commission

Other fees may apply. Your capital is at risk.

  • Unlimited trades, with no dealing charges or management fees
  • If your trades get copied you can earn extra money
  • Create an account today in a few minutes

Fees for buying 100x Citius Pharmaceuticals shares with popular platforms

Both exchange rates and share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.

Platform Platform fee Min. initial deposit Trading fee estimate
Fineco logo £0 No minimum £4.24
£139.17 total
Capital at risk
eToro Free Stocks logo £0 $200 £0.67
£135.61 total
Capital at risk
Degiro Share Dealing logo £0 £0.01 £0.86
£135.79 total
Capital at risk
Stake logo £0 £50 £0.96
£135.90 total
Capital at risk
Hargreaves Lansdown Fund and Share Account logo £0 £1 £13.59
£148.52 total
Capital at risk
interactive investor Trading Account logo £9.99 per month No minimum £10.30
£145.24 total
Capital at risk
Halifax Share Dealing Account logo £36 per year £20 £14.48
£149.41 total
Capital at risk

Full comparison of share dealing platforms

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.

Is it a good time to buy Citius Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Citius Pharmaceuticals price performance over time

Historical closes compared with the last close of $1.865

1 week (2021-04-09) 2.47%
1 month (2021-03-16) 0.81%
3 months (2021-01-15) 65.04%
6 months (2020-10-15) 75.94%
1 year (2020-04-15) 166.47%
2 years (2019-04-15) 59.40%
3 years (2018-04-13) -37.83%
5 years (2016-04-12) inf%


Gross profit TTM $0
Return on assets TTM -44.4%
Return on equity TTM -92.57%
Profit margin 0%
Book value $0.453
Market capitalisation $232.9 million

TTM: trailing 12 months

How to short and sell Citius Pharmaceuticals shares

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "CTXR.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 11.0 million Citius Pharmaceuticals shares held short by investors – that's known as the "short interest". This figure is 51.3% up from 7.3 million last month.

There are a few different ways that this level of interest in shorting Citius Pharmaceuticals shares can be evaluated.

Short interest ratio (SIR)

Citius Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Citius Pharmaceuticals shares currently shorted divided by the average quantity of Citius Pharmaceuticals shares traded daily (recently around 10.1 million). Citius Pharmaceuticals's SIR currently stands at 1.09. In other words for every 100,000 Citius Pharmaceuticals shares traded daily on the market, roughly 1090 shares are currently held short.

However Citius Pharmaceuticals's short interest can also be evaluated against the total number of Citius Pharmaceuticals shares, or, against the total number of tradable Citius Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Citius Pharmaceuticals's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Citius Pharmaceuticals shares in existence, roughly 80 shares are currently held short) or 0.0902% of the tradable shares (for every 100,000 tradable Citius Pharmaceuticals shares, roughly 90 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Citius Pharmaceuticals.

Find out more about how you can short Citius Pharmaceuticals stock.

Citius Pharmaceuticals share dividends

We're not expecting Citius Pharmaceuticals to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.

Have Citius Pharmaceuticals's shares ever split?

Citius Pharmaceuticals's shares were split on a 1:15 basis on 8 June 2017. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Citius Pharmaceuticals shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Citius Pharmaceuticals shares which in turn could have impacted Citius Pharmaceuticals's share price.

Share price volatility

Over the last 12 months, Citius Pharmaceuticals's shares have ranged in value from as little as $0.64 up to $2.5. A popular way to gauge a stock's volatility is its "beta".

CTXR.US volatility(beta: 1.54)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Citius Pharmaceuticals's is 1.5378. This would suggest that Citius Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Win £500 to get your trading started

Subscribe to trending stock alerts for a chance to win

By submitting, you agree to the Finder Privacy and Cookies Policy and Terms of Use

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site